Professor | Duan Yi | Asia Growth Partners

	Upload Avatar (500 x 500)
Name	Duan Yi
Contact Information	yduan@ustc.edu.cn
Language ability	English, Chinese
Province	Anhui

Upload Avatar (500 x 500)

Name

Duan Yi

Contact Information

yduan@ustc.edu.cn

Language ability

English, Chinese

Province

Anhui

University/Lab Affiliation and Title	University of Science and Technology of China
Faculty	Basic Medical Sciences
Academic Background & Achievements	2011-2016 PhD in Biochemistry: Texas A&M University 2007-2011 Bachelor's in Biological Sciences: University of Science and Technology of China Published 35 SCI papers, 17 with IF>10 Cited over 2700 times, highest single citation 485 times
Work Experience	2022-present - University of Science and Technology of China - Professor, Doctoral Supervisor 2017-2022 - University of California, San Diego - Postdoctoral Research Scholar
Awards	2019 AASLD Early Career Investigator Award

University/Lab Affiliation and Title

University of Science and Technology of China

Faculty

Basic Medical Sciences

Academic Background & Achievements

2011-2016 PhD in Biochemistry: Texas A&M University
2007-2011 Bachelor's in Biological Sciences: University of Science and Technology of China
Published 35 SCI papers, 17 with IF>10
Cited over 2700 times, highest single citation 485 times

Work Experience

2022-present - University of Science and Technology of China - Professor, Doctoral Supervisor
2017-2022 - University of California, San Diego - Postdoctoral Research Scholar

Awards

2019 AASLD Early Career Investigator Award

Areas of Focus	Impact of gut microbiota on metabolic and immune diseases, especially chronic liver disease Development and application of microbiome-related biotherapies, especially phage therapy Development of new technologies and methods related to gut microbiota research
Publications	Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease., Duan Y, Llorente C, Lang S, Brandl K, Chu H, Jiang L, et al., 2019 Novel tripeptide RKH derived from Akkermansia muciniphila protects against lethal sepsis., Xie S, Li J, Lyu F, Xiong Q, et al., Duan Y, Jiang Y, Zhou H, Chen P., 2023 Phage therapy in gut microbiome., Chen X, Mendes BG, Alves BS, Duan Y., 2023 Bacteriophages and their potential for treatment of gastrointestinal diseases., Duan Y, Young R, Schnabl B., 2022 Immune response of an oral Enterococcus faecalis phage cocktail in a mouse model of ethanol-induced liver disease., Mendes BG, Duan Y, Schnabl B., 2022 CRIg on liver macrophages clears pathobionts and protects against alcoholic liver disease., Duan Y, Chu H, Brandl K, Jiang L, Zeng S, Mendes BG, et al., 2021 The Candida albicans exotoxin Candidalysin promotes alcohol-associated liver disease., Chu H, Duan Y, Lang S, Jiang L, Wang Y, Llorente C, et al., 2020 Functional microbiomics reveals alterations of the gut microbiome and host co-metabolism in patients with alcoholic hepatitis., Gao B, Duan Y, Lang S, Barupal D, Wu TC, Valdiviez L, et al., 2020 The DnaA inhibitor SirA acts in the same pathway as Soj (ParA) to facilitate oriC segregation during Bacillus subtilis sporulation., Duan Y, Huey JD, Herman JK, 2016 YodL and YisK possess shape-modifying activities that are suppressed by mutations in Bacillus subtilismreB and mbl., Duan Y, Sperber AM, Herman JK, 2016 Candida albicans-specific Th17 cell-mediated response contributes to alcohol-associated liver disease., Zeng S, Rosati E, Saggau C, Messner B, Chu H, Duan Y, Hartmann P, et al., 2023 The fecal mycobiome in non-alcoholic fatty liver disease., Demir M, Lang S, Hartmann P, Duan Y, Martin A, Miyamoto Y, Bondareva M, et al., 2022 Intestinal virome and therapeutic potential of bacteriophages in liver disease., Hsu CL, Duan Y, Fouts DE, Schnabl B., 2021 Gut microbiome directs hepatocytes to recruit MDSC and promote cholangiocarcinoma., Zhang Q, Ma C, Duan Y, Heinrich B, Rosato U, Diggs L, et al., 2021 Intestinal virome in patients with alcoholic hepatitis., Jiang L, Lang S, Duan Y, Zhang X, Gao B, Chopyk J, et al., 2020 Intestinal fungal dysbiosis and systemic immune response to fungi in patients with alcoholic hepatitis., Lang S, Duan Y, Liu J, Torralba MG, Kuelbs C, Ventura-Cots M, et al., 2020 Intestinal virome signature associated with severity of nonalcoholic fatty liver disease., Lang S, Demir M, Martin A, Jiang L, Zhang X, Duan Y, Gao B, Wisplinghoff H, et al., 2020 Bacteria engineered to produce IL-22 in intestine induce expression of REG3G to reduce ethanol-induced liver disease in mice., Hendrikx T, Duan Y, Wang Y, Oh JH, Alexander LM, Huang W, et al., 2019 Small Metabolites, possible big changes: a microbiota-centered view of non-alcoholic fatty liver disease., Chu H, Duan Y, Yang L, and Schnabl B, 2019

Areas of Focus

Impact of gut microbiota on metabolic and immune diseases, especially chronic liver disease
Development and application of microbiome-related biotherapies, especially phage therapy
Development of new technologies and methods related to gut microbiota research

Publications

Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease., Duan Y, Llorente C, Lang S, Brandl K, Chu H, Jiang L, et al., 2019
Novel tripeptide RKH derived from Akkermansia muciniphila protects against lethal sepsis., Xie S, Li J, Lyu F, Xiong Q, et al., Duan Y, Jiang Y, Zhou H, Chen P., 2023
Phage therapy in gut microbiome., Chen X, Mendes BG, Alves BS, Duan Y., 2023
Bacteriophages and their potential for treatment of gastrointestinal diseases., Duan Y, Young R, Schnabl B., 2022
Immune response of an oral Enterococcus faecalis phage cocktail in a mouse model of ethanol-induced liver disease., Mendes BG, Duan Y, Schnabl B., 2022
CRIg on liver macrophages clears pathobionts and protects against alcoholic liver disease., Duan Y, Chu H, Brandl K, Jiang L, Zeng S, Mendes BG, et al., 2021
The Candida albicans exotoxin Candidalysin promotes alcohol-associated liver disease., Chu H, Duan Y, Lang S, Jiang L, Wang Y, Llorente C, et al., 2020
Functional microbiomics reveals alterations of the gut microbiome and host co-metabolism in patients with alcoholic hepatitis., Gao B, Duan Y, Lang S, Barupal D, Wu TC, Valdiviez L, et al., 2020
The DnaA inhibitor SirA acts in the same pathway as Soj (ParA) to facilitate oriC segregation during Bacillus subtilis sporulation., Duan Y, Huey JD, Herman JK, 2016
YodL and YisK possess shape-modifying activities that are suppressed by mutations in Bacillus subtilismreB and mbl., Duan Y, Sperber AM, Herman JK, 2016
Candida albicans-specific Th17 cell-mediated response contributes to alcohol-associated liver disease., Zeng S, Rosati E, Saggau C, Messner B, Chu H, Duan Y, Hartmann P, et al., 2023
The fecal mycobiome in non-alcoholic fatty liver disease., Demir M, Lang S, Hartmann P, Duan Y, Martin A, Miyamoto Y, Bondareva M, et al., 2022
Intestinal virome and therapeutic potential of bacteriophages in liver disease., Hsu CL, Duan Y, Fouts DE, Schnabl B., 2021
Gut microbiome directs hepatocytes to recruit MDSC and promote cholangiocarcinoma., Zhang Q, Ma C, Duan Y, Heinrich B, Rosato U, Diggs L, et al., 2021
Intestinal virome in patients with alcoholic hepatitis., Jiang L, Lang S, Duan Y, Zhang X, Gao B, Chopyk J, et al., 2020
Intestinal fungal dysbiosis and systemic immune response to fungi in patients with alcoholic hepatitis., Lang S, Duan Y, Liu J, Torralba MG, Kuelbs C, Ventura-Cots M, et al., 2020
Intestinal virome signature associated with severity of nonalcoholic fatty liver disease., Lang S, Demir M, Martin A, Jiang L, Zhang X, Duan Y, Gao B, Wisplinghoff H, et al., 2020
Bacteria engineered to produce IL-22 in intestine induce expression of REG3G to reduce ethanol-induced liver disease in mice., Hendrikx T, Duan Y, Wang Y, Oh JH, Alexander LM, Huang W, et al., 2019
Small Metabolites, possible big changes: a microbiota-centered view of non-alcoholic fatty liver disease., Chu H, Duan Y, Yang L, and Schnabl B, 2019

Gut Microbiota Metabolic Diseases Immune Diseases Chronic Liver Disease Biotherapies Phage Therapy Microbiome New Technologies Molecular Mechanisms Clinical Value

Lan Yan Zheng - China Medical University

Yingchao Hu - Nanjing Medical University

Ruimao Zheng - Peking University

View All

Personal Information

Academic Information

Research

Contact us

No account yet?

Personal Information

Academic Information

Research

Contact us